Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
$4.41
+0.2%
$5.21
$3.95
$30.40
$57.29M0.46139,087 shs51,307 shs
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
$0.85
$0.46
$17.51
$978.01M-0.1390,307 shs22,300 shs
Kadmon Holdings Inc stock logo
KDMN
Kadmon
$9.50
$9.50
$3.19
$9.50
$1.70BN/A5.11 million shs1,052 shs
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
$17.86
+1.8%
$19.24
$16.84
$36.64
$499.72M1.64299,589 shs175,728 shs
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
$1.08
$0.77
$5.95
$187.12M1.712.01 million shs2.13 million shs
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
+0.23%+6.01%-9.26%-24.62%-84.46%
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
0.00%+1,700.00%+1,700.00%+4,704.97%+3,360.07%
Kadmon Holdings Inc stock logo
KDMN
Kadmon
0.00%0.00%0.00%0.00%0.00%
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
+1.77%-0.22%-11.36%-29.41%-37.07%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
4.0882 of 5 stars
2.52.00.03.92.23.31.9
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
1.5879 of 5 stars
3.30.00.04.80.00.80.6
Kadmon Holdings Inc stock logo
KDMN
Kadmon
N/AN/AN/AN/AN/AN/AN/AN/A
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
1.6819 of 5 stars
0.03.01.72.62.11.71.3
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
1.00
Sell$17.00285.49% Upside
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
2.50
Moderate Buy$0.75∞ Upside
Kadmon Holdings Inc stock logo
KDMN
Kadmon
N/AN/AN/AN/A
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
1.00
SellN/AN/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/A

Current Analyst Ratings

Latest FIXX, KDMN, EGRX, ZIOP, and RDUS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/28/2024
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
Seaport Res Ptn
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeNeutral ➝ Sell
(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
$316.61M0.18$3.80 per share1.16$17.94 per share0.25
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
$1.16M0.00N/AN/A$1.26 per share0.00
Kadmon Holdings Inc stock logo
KDMN
Kadmon
N/AN/AN/AN/AN/AN/A
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
$2.88B0.17$4.20 per share4.25$30.29 per share0.59
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/A$0.58 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
$35.64M$1.183.74N/AN/AN/AN/A5/14/2024 (Estimated)
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
-$112.96M-$1.96N/AN/AN/A-4,779.31%-102.52%-74.91%5/9/2024 (Estimated)
Kadmon Holdings Inc stock logo
KDMN
Kadmon
N/AN/A0.00N/AN/AN/AN/AN/A
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
-$25.79M-$2.28N/A19.63N/A-2.28%-1.73%-0.88%6/25/2024 (Estimated)
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
-$79.98M-$0.43N/AN/AN/AN/A-92.84%-72.46%N/A

Latest FIXX, KDMN, EGRX, ZIOP, and RDUS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/4/2024Q2 2024
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
-$1.09-$1.04+$0.05-$0.89$626.35 million$621.06 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
N/AN/AN/AN/AN/A
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
N/AN/AN/AN/AN/A
Kadmon Holdings Inc stock logo
KDMN
Kadmon
N/AN/AN/AN/AN/A
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
$0.754.20%N/AN/A N/A
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
N/AN/AN/AN/AN/A

Latest FIXX, KDMN, EGRX, ZIOP, and RDUS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/1/2024
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
quarterly$0.18753.7%4/19/20244/22/20245/6/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
N/AN/AN/A
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
N/A
7.25
7.25
Kadmon Holdings Inc stock logo
KDMN
Kadmon
N/AN/AN/A
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
0.43
1.96
0.92
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
0.18
3.43
3.43

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
85.36%
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
31.32%
Kadmon Holdings Inc stock logo
KDMN
Kadmon
N/A
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
78.11%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
51.03%

Insider Ownership

CompanyInsider Ownership
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
28.90%
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
16.10%
Kadmon Holdings Inc stock logo
KDMN
Kadmon
N/A
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
5.70%
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
5.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Eagle Pharmaceuticals, Inc. stock logo
EGRX
Eagle Pharmaceuticals
13412.99 million9.23 millionOptionable
Homology Medicines, Inc. stock logo
FIXX
Homology Medicines
758.13 million48.77 millionOptionable
Kadmon Holdings Inc stock logo
KDMN
Kadmon
N/A178.52 millionN/AOptionable
Radius Recycling, Inc. stock logo
RDUS
Radius Recycling
3,35327.98 million26.39 millionOptionable
ZIOPHARM Oncology, Inc. stock logo
ZIOP
ZIOPHARM Oncology
105216.15 million204.91 millionOptionable

FIXX, KDMN, EGRX, ZIOP, and RDUS Headlines

SourceHeadline
Childhood CancersChildhood Cancers
curetoday.com - February 17 at 5:57 PM
Alx Oncology Holdings (ALXO)Alx Oncology Holdings (ALXO)
investing.com - February 10 at 8:15 PM
Pediatric Hematology-Oncology FellowshipPediatric Hematology-Oncology Fellowship
bcm.edu - February 5 at 8:39 AM
Alaunos Therapeutics: Other Events, Financial Statements And ExhibitsAlaunos Therapeutics: Other Events, Financial Statements And Exhibits
cbonds.com - January 31 at 9:44 AM
CG Oncology IncCG Oncology Inc
reuters.com - January 31 at 4:43 AM
Oncology Nurses Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer PatientsOncology Nurses' Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer Patients
medscape.com - December 21 at 3:43 PM
Immuno-OncologyImmuno-Oncology
ajmc.com - December 19 at 3:21 PM
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
markets.businessinsider.com - December 18 at 8:18 AM
Exploring Patient-Centered Handoffs in Surgical OncologyExploring Patient-Centered Handoffs in Surgical Oncology
medscape.com - December 10 at 7:36 PM
Association of Community Cancer CentersAssociation of Community Cancer Centers
ajmc.com - October 14 at 2:50 PM
Oncology News and ResearchOncology News and Research
news-medical.net - September 19 at 5:53 PM
WBSPH 2024 - OncologyWBSPH 2024 - Oncology
newsweek.com - September 15 at 8:49 PM
Kris on OncologyKris on Oncology
medscape.com - September 6 at 11:16 PM
Gauging Ziopharms Chances for Positive Sarcoma Drug Trial ResultsGauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results
thestreet.com - August 29 at 6:23 AM
Oncology Cases & QuizzesOncology Cases & Quizzes
medscape.com - August 14 at 6:15 PM
Ziopharm’s palifosfamide fails in first-line STS…Ziopharm’s palifosfamide fails in first-line STS…
investing.com - June 21 at 12:05 AM
Weber on OncologyWeber on Oncology
medscape.com - June 19 at 2:11 PM
A Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in MelanomaA Brain, A Heart, and the Courage: Balancing Benefit and Toxicity of Immunotherapy in Melanoma
ascopubs.org - June 17 at 8:43 AM
ALX Oncology Holdings Inc Ordinary SharesALX Oncology Holdings Inc Ordinary Shares
morningstar.com - June 15 at 6:54 PM
Division of Pediatric Hematology and OncologyDivision of Pediatric Hematology and Oncology
slu.edu - June 13 at 3:50 PM
Division of Hematology and Medical OncologyDivision of Hematology and Medical Oncology
slu.edu - June 13 at 3:50 PM
Intratumoral Cancer Therapies Global Market Report 2023Intratumoral Cancer Therapies Global Market Report 2023
finance.yahoo.com - June 9 at 1:32 PM
Natural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.coNatural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.co
marketwatch.com - May 11 at 9:52 PM
VC Identifies 3 Startups That Will Shake Up the Future of Cancer CareVC Identifies 3 Startups That Will Shake Up the Future of Cancer Care
medcitynews.com - May 10 at 1:58 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Eagle Pharmaceuticals logo

Eagle Pharmaceuticals

NASDAQ:EGRX
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
Homology Medicines logo

Homology Medicines

NASDAQ:FIXX
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
Kadmon logo

Kadmon

NYSE:KDMN
Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. Its clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies.
Radius Recycling logo

Radius Recycling

NASDAQ:RDUS
Radius Recycling, Inc. recycles ferrous and nonferrous metal, and manufactures finished steel products worldwide. The company acquires, processes, and recycles salvaged vehicles, rail cars, home appliances, industrial machinery, manufacturing scrap, and construction and demolition scrap. It offers recycled ferrous metal, a feedstock used in the production of finished steel products; and nonferrous products, including mixed metal joint products recovered from the shredding process, such as zorba, zurik, aluminum, copper, stainless steel, nickel, brass, titanium, lead, and high temperature alloys. The company also procures salvaged vehicles and sells serviceable used auto parts from these vehicles through its retail self-service auto parts stores. In addition, it produces various finished steel products using ferrous recycled metal and other raw materials, as well as semi-finished goods, which include billets; and finished goods consisting of rebar, coiled rebar, wire rods, merchant bars, and other specialty products. Further, the company sells catalytic converters to specialty processors that extract the nonferrous precious metals, including platinum, palladium, and rhodium; and ferrous and nonferrous recycled metal products to steel mills, foundries, refineries, smelters, wholesalers, and recycled metal processors, as well as finished steel customers, such as steel service centers, construction industry subcontractors, steel fabricators, wire drawers, and major farm and wood products suppliers. It also provides recycling and related services, including scrap brokerage, certified destruction, automotive parts recycling, railcar dismantling, and reverse logistics under 3PR brand name. Radius Recycling, Inc. was formerly known as Schnitzer Steel Industries, Inc. and changed its name to Radius Recycling, Inc. in January 2024. Radius Recycling, Inc. was founded in 1906 and is headquartered in Portland, Oregon.
ZIOPHARM Oncology logo

ZIOPHARM Oncology

NASDAQ:ZIOP
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.